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Telaprevir Activity in Treatment-Naive Patients Infected With Hepatitis C Virus Genotype 4 TO THE EDITOR-Benhamou et al demonstrated that the tolerability and pharmacokinetics of telaprevir in patients infected with hepatitis C virus (HCV) genotype 4 were similar to those found in HCV genotype 1 patients [1] . In their study, patients infected with HCV genotype 4 were randomly assigned to receive (1) telaprevir monotherapy for 15 days; (2) telaprevir, pegylated interferon alfa2a, and ribavirin (TPR) for 15 days; or (3) placebo, pegylated interferon alfa-2a, and ribavirin (PR) for 15 days. After the initial 15-day treatment period, study drugs in each group were replaced with standard PR treatment, which was administered for an additional 46-48 weeks.
Findings from the study by Benhamou et al supported the investigation of TPR for 12 weeks, followed by PR for an additional 36 weeks, in HCV genotype 4-infected patients. With institutional review board approval, we performed a chart review of HCV genotype 4-infected patients who received TPR at Mount Sinai Hospital, New York, between April 2011 and October 2012. The aim was to determine the rate of sustained virologic response at week 24 of follow-up (SVR24), which was defined as undetectable HCV RNA 24 weeks after the end of treatment. Patients who were chronically infected with HCV genotype 4 and received at least 1 dose of telaprevir were included.
The demographic characteristics of our patients are described in Table 1 . Patients received the TPR regimen approved for treatment of HCV genotype 1 infection (ie, TPR for 12 weeks then PR for an additional 12 weeks [response-guided therapy] or 36 weeks), with the following exceptions [2] . Patient 1 began TPR treatment, and after 2 weeks it was discovered that he was given 200 mg ribavirin twice daily instead of 600 mg twice daily. Telaprevir therapy was mistakenly discontinued after 8 weeks, and PR treatment was discontinued because of virologic breakthrough (ie, HCV RNA was detected after the HCV RNA level had fallen below the limit of detection during treatment) that occurred after 41 weeks of treatment.
Patient 3 initiated TPR therapy, decided to stop treatment 40 weeks after initiation, and achieved a SVR24. Patient 5 initiated TPR therapy and, after 11 weeks, discontinued telaprevir treatment because of adverse events. Patient 6 received nitazoxanide and PR treatment, and his HCV RNA load 4 weeks later had decreased to 5414 IU/mL. He discontinued nitazoxanide therapy at this time because of adverse events. A 12-week course of telaprevir treatment was added to the existing regimen after 22 weeks. By week 31 of treatment, the HCV RNA level in patient 6 had fallen below the limit of quantification, but HCV RNA was detectable 6 weeks after the end of treatment. Patient 7 initiated TPR treatment, but it was discontinued after 2 weeks because of adverse events (hepatic encephalopathy, ascites, thrombocytopenia, and neutropenia). Decompensation continued, and the patient was discharged to hospice 13 weeks after the end of treatment, where he died.
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